Clinical trials: First-line Treatment of Metastatic Pancreatic Cancer
- Condition First-line Treatment of Metastatic Pancreatic Cancer
- Funder type Industry (pharma, biotech, devices)
Adenocarcinoma of the Pancreas, Advanced Solid Tumors
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival.
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas
- Trial name
- GAMMA (NCT01231347)
- Testing
- AMG 479, gemcitabine
- Where
- 152 sites in United States, Australia and 30 more
- Volunteers
- 800 people
- Sponsor
- NantCell, Inc.
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02024633
- Testing
- icotinib, Gemcitabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Cancer
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in…
- Trial name
- NCT05859750
- Testing
- AK104, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Akeso
Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
This is a multi-center, 2-part study of AMG 655, AMG 479 or AMG 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
- Trial name
- NCT00630552
- Testing
- AMG 479, AMG 655
- Where
- 44 sites in United States
- Volunteers
- 138 people
- Sponsor
- NantCell, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Trial name
- NCT06646055
- Testing
- AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Akeso
Pancreatic Cancer, Pancreatic Cancer Metastatic
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- MAPKeeper 301 (NCT07562152)
- Testing
- Atebimetinib, GnP, mGnP
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 570 people
- Sponsor
- Immuneering Corporation
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer.
- Trial name
- NCT01472198
- Testing
- Simtuzumab, Gemcitabine
- Where
- 57 sites in United States, Russia
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic…
- Trial name
- NCT07859085
- Testing
- GDC-7035, Panitumumab, mFOLFOX6
- Volunteers
- 388 people
- Sponsor
- Genentech, Inc.
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor.
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT03816163
- Testing
- zolbetuximab, nab-paclitaxel, gemcitabine
- Where
- 136 sites in United States, Australia and 11 more
- Volunteers
- 393 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis and limited treatment options following failure of first-line therapy.
- Trial name
- MATTERS-2 (NCT07711067)
- Testing
- Whole-body hyperthermia, Standard-of-Care Systemic therapy
- Where
- 4 sites in Belgium, Spain
- Volunteers
- 95 people
- Sponsor
- ElmediX
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 305 (NCT07621718)
- Testing
- Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate)
- Where
- 25 sites in United States, Austria and 3 more
- Volunteers
- 670 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Cancer
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003780
- Testing
- tumor infiltrating lymphocyte therapy, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Meyer Pharmaceuticals
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 104 sites in United States, Brazil and 9 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Pancreatic Cancer
QUILT-3.088: NANT Pancreatic Cancer Vaccine
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
- Trial name
- NCT03563144
- Testing
- Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Metastatic Pancreatic Cancer
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
- Trial name
- NCT00326911
- Testing
- cetuximab, bevacizumab, gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
The purpose of this study is to assess the efficacy and safety of AZD6244 (ARRY-142886)versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine.
- Trial name
- NCT00372944
- Testing
- AZD6244, capecitabine
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
- Trial name
- NCT07232875
- Testing
- HRS-4642 + AG
- Where
- China
- Volunteers
- 588 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Neoplasms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
- Trial name
- NCT06767813
- Testing
- TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 303 (NCT07491445)
- Testing
- daraxonrasib, gemcitabine, nab-paclitaxel
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- Revolution Medicines, Inc.